Orchid Pharma per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹1.23₹1.66₹19.65₹19.06₹11.35
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹1.23₹1.66₹19.65₹19.06₹11.35
₹261.22₹261.22₹249.86₹230.58₹168.72
₹179.22₹205.86₹181.77₹161.55₹163.14
—₹20.98₹3.79₹24.84₹4.55
−₹44.08−₹44.08−₹25.81₹12.06−₹16.25
6.06.05.15.14.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health
₹ CrorePeersFDCGUJTHEMIOLCPMOREPENLABRPGLIFEGUFICBIOINNOVACAPUNICHEMLABMcap ₹5,180 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS11.3519.0619.651.661.23
Diluted EPS11.3519.0619.651.661.23
Book Value per Share168.72230.58249.86261.22261.22
Revenue per Share163.14161.55181.77205.86179.22
Cash Flow per Share4.5524.843.7920.98—
Free Cash Flow per Share-16.2512.06-25.81-44.08-44.08
Shares Outstanding (cr)4.15.15.16.06.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.